<DOC>
	<DOC>NCT00002349</DOC>
	<brief_summary>To compare the antiviral effect of stavudine ( d4T ) versus placebo in patients with evidence of recent HIV infection. Also, to compare the immunologic effects and effects on quality of life of d4T in these patients.</brief_summary>
	<brief_title>A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.</brief_title>
	<detailed_description>Patients receive d4T or placebo every 12 hours for 4 weeks, after which dose decreases (or placebo) every 12 hours. Treatment continues for at least 48 weeks.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Recent HIV infection. No prior antiretroviral therapy. No acute opportunistic infection at study entry. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Intractable diarrhea. Bilateral peripheral neuropathy. Any other condition that would preclude study therapy. Concurrent Medication: Excluded: Myelosuppressive, neurotoxic, or hepatotoxic drugs. Patients with the following prior condition are excluded: History of bilateral peripheral neuropathy. Prior Medication: Excluded: Prior antiretroviral therapy. Myelosuppressive, neurotoxic, or cytotoxic agents within 3 months prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Stavudine</keyword>
</DOC>